Needham & Company Reiterates Revance Therapeutic (RVNC) at Buy with $25 PT, New Financing is a Positive Development
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $25.00 price target on Revance Therapeutic (NASDAQ: RVNC), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
